Mycamine Related Published Studies
Well-designed clinical trials related to Mycamine (Micafungin)
Outcomes with micafungin in patients with candidaemia or invasive candidiasis due to Candida glabrata and Candida krusei. [2011.02]
Lack of pharmacokinetic drug interaction between oral posaconazole and caspofungin or micafungin. [2011.01]
Intravenous micafungin versus voriconazole for chronic pulmonary aspergillosis: a multicenter trial in Japan. [2010.11]
Factors related to survival and treatment success in invasive candidiasis or candidemia: a pooled analysis of two large, prospective, micafungin trials. [2010.02]
[Comparison of micafungin and fosfluconazole as prophylaxis for invasive fungal infection during neutropenia in children undergoing chemotherapy and hematopoietic stem cell transplantation] [2009.12]
Treatment of candidemia and invasive candidiasis in the intensive care unit: post hoc analysis of a randomized, controlled trial comparing micafungin and liposomal amphotericin B. [2009]
Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial. [2008.09]
Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. [2007.10.01]
Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. [2007.05.05]
Steady-state pharmacokinetics of micafungin and voriconazole after separate and concomitant dosing in healthy adults. [2007.02]
International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia. [2005.10]
A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal candidiasis. [2005.04.01]
Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant. [2005.04]
Well-designed clinical trials possibly related to Mycamine (Micafungin)
Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections. [2009]
Other research related to Mycamine (Micafungin)
Randomised, multicentre trial of micafungin vs. an institutional standard regimen
for salvage treatment of invasive aspergillosis. [2015]
Clinical pharmacodynamic index identification for micafungin in esophageal
candidiasis: dosing strategy optimization. [2013]
A double-blind comparative study of the safety and efficacy of caspofungin versus
micafungin in the treatment of candidiasis and aspergillosis. [2013]
Drug interactions between micafungin at high doses and cyclosporine A in febrile
neutropenia patients after allogeneic hematopoietic stem cell transplantation. [2012]
Efficacy and safety of micafungin for invasive candida infections: a
meta-analysis of randomized controlled trials. [2012]
Fractal geometry and the pharmacometrics of micafungin in overweight, obese, and extremely obese people. [2011.11]
Efficacy and safety of micafungin for treatment of serious Candida infections in patients with or without malignant disease. [2011.11]
Efficacy and safety of micafungin as an empirical therapy for invasive fungal infections in patients with hematologic disorders: a multicenter, prospective study. [2011.10]
The comparison of solitary topical micafungin or fluconazole application in the treatment of Candida fungal keratitis. [2011.10]
Pharmacokinetics of micafungin in HIV positive patients with confirmed esophageal candidiasis. [2011.09.29]
Disseminated Candidiasis caused by Candida albicans with amino acid substitutions in Fks1 at position Ser645 cannot be successfully treated with micafungin. [2011.07]
Safety of micafungin in pediatric clinical trials. [2011.06]
Higher clearance of micafungin in neonates compared with adults: role of age-dependent micafungin serum binding. [2011.05]
Multicenter comparison of the Vitek 2 antifungal susceptibility test with the CLSI broth microdilution reference method for testing caspofungin, micafungin, and posaconazole against Candida spp. [2011.05]
Use of pharmacokinetic-pharmacodynamic analyses to optimize therapy with the systemic antifungal micafungin for invasive candidiasis or candidemia. [2011.05]
Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin and its impact on use and costs: review of the literature. [2011.04.28]
Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin:review of the literature. [2011.04.28]
Pharmacology and metabolism of anidulafungin, caspofungin and micafungin in the treatment of invasive candidosis: review of the literature. [2011.04.28]
[Is micafungin useful in the prophylaxis of invasive fungal disease in hematological patients?]. [2011.03]
[Drug interactions in critically-ill patients. An important factor in the use of micafungin?]. [2011.03]
[Liver toxicity of micafungin. Is this drug safe?]. [2011.03]
[Why might micafungin be the drug of choice in pediatric patients?]. [2011.03]
[Scientific evidence supporting the use of micafungin in the treatment of invasive candidiasis]. [2011.03]
[Differential pharmacokinetic characteristics of micafungin. Experience in special populations]. [2011.03]
Accumulated safety data of micafungin in therapy and prophylaxis in fungal diseases. [2011.03]
Safety of micafungin in infants: insights into optimal dosing. [2011.03]
Nebulizer delivery of micafungin aerosols. [2011.01]
First case report of acquired pure red cell aplasia associated with micafungin. [2011]
Outcomes with micafungin in patients with candidaemia or invasive candidiasis due
to Candida glabrata and Candida krusei. [2011]
Lack of pharmacokinetic drug interaction between oral posaconazole and
caspofungin or micafungin. [2011]
[Experience of micafungin in patients requiring extrarenal depuration]. [2010.12]
Efficacy and safety of micafungin for treating febrile neutropenia in hematological malignancies. [2010.11]
Analysis of Candida glabrata strains with reduced sensitivity to micafungin in vitro isolated from a patient with persistent Candidemia. [2010.09]
Intravenous micafungin versus voriconazole for chronic pulmonary aspergillosis: A multicenter trial in Japan. [2010.08.24]
Population pharmacokinetics of micafungin in neonates and young infants. [2010.06]
Lack of Pharmacokinetic Drug Interaction Between Oral Posaconazole and Caspofungin or Micafungin. [2010.05.20]
Successful treatment of Aspergillus liver abscesses in a patient with acute monoblastic leukemia using combination antifungal therapy including micafungin as a key drug. [2010.05]
Antifungal prophylaxis with micafungin in neutropenic patients with hematological malignancies. [2010.05]
Evaluation of caspofungin or micafungin as empiric antifungal therapy in adult patients with persistent febrile neutropenia: a retrospective, observational, sequential cohort analysis. [2010.04]
Activity of aminocandin (IP960; HMR3270) compared with amphotericin B, itraconazole, caspofungin and micafungin in neutropenic murine models of disseminated infection caused by itraconazole-susceptible and -resistant strains of Aspergillus fumigatus. [2010.02]
Micafungin concentrations from brain tissue and pancreatic pseudocyst fluid. [2010.02]
Safety and pharmacokinetics of repeat-dose micafungin in young infants. [2010.01]
Intravenous micafungin versus voriconazole for chronic pulmonary aspergillosis: a
multicenter trial in Japan. [2010]
Factors related to survival and treatment success in invasive candidiasis or
candidemia: a pooled analysis of two large, prospective, micafungin trials. [2010]
Case of fatal Blastoschizomyces capitatus infection occurring in a patient receiving empiric micafungin therapy. [2009.12]
Refractory neonatal candidemia and high-dose micafungin pharmacotherapy. [2009.11]
Antifungal prophylaxis with micafungin in patients treated for childhood cancer. [2009.10]
Assessment of micafungin regimens by pharmacokinetic-pharmacodynamic analysis: a dosing strategy for Aspergillus infections. [2009.10]
Pharmacokinetics of prophylactic micafungin in very-low-birth-weight infants. [2009.09]
Cost-effectiveness analysis of micafungin versus caspofungin for treatment of systemic Candida infections in the UK. [2009.08]
Efficacy of combination antifungal therapy with intraperitoneally administered micafungin and aerosolized liposomal amphotericin B against murine invasive pulmonary aspergillosis. [2009.08]
Combination therapy with micafungin and amphotericin B for invasive pulmonary aspergillosis in an immunocompromised mouse model. [2009.08]
Clinical effects of micafungin, a novel echinocandin antifungal agent, on systemic fungal infections in surgery, emergency, and intensive-care medicine: evaluation using the AKOTT algorithm. [2009.08]
Micafungin - the newest echinocandin. [2009.06]
Cost-effectiveness analysis of micafungin versus fluconazole for prophylaxis of invasive fungal infections in patients undergoing hematopoietic stem cell transplantation in Korea. [2009.05]
Pharmacokinetics of an elevated dosage of micafungin in premature neonates. [2009.05]
Efficacy of micafungin in treating four premature infants with candidiasis. [2009.04]
The impact of total bilirubin on plasma micafungin levels in living-donor liver transplantation recipients with severe liver dysfunction. [2009.04]
Hepatitis associated with micafungin use in a preterm infant. [2009.04]
[Future role of micafungin in the treatment of invasive mycoses caused by filamentous fungi] [2009.03.31]
[Micafungin in invasive candidiasis among oncohematological patients] [2009.03.31]
[Clinical use of micafungin for the treatment of invasive candidiasis in critical ill patients] [2009.03.31]
[Micafungin for therapy of invasive candidiasis in solid organ transplant recipients] [2009.03.31]
[Micafungin in pediatric and adolescent patients] [2009.03.31]
[Micafungin for the treatment of neonatal invasive candidiasis] [2009.03.31]
[In vitro antifungal activity of micafungin] [2009.03.31]
[Micafungin: experimental therapy of fungal infections in animal models] [2009.03.31]
[Pharmacodynamics and pharmacokinetics of micafungin in adults, children and neonate] [2009.03.31]
Micafungin plus fluconazole in an infected knee with retained hardware due to Candida albicans. [2009.03]
Micafungin-induced immune hemolysis attacks. [2009.03]
Bronchopulmonary disposition of micafungin in healthy adult volunteers. [2009.03]
Breakthrough disseminated zygomycosis induced massive gastrointestinal bleeding in a patient with acute myeloid leukemia receiving micafungin. [2009.02]
Efficacy and safety of micafungin, an echinocandin antifungal agent, on invasive fungal infections in patients with hematological disorders. [2009.01]
Micafungin: a review of its use in the prophylaxis and treatment of invasive Candida infections in pediatric patients. [2009]
Initial characterization of micafungin pulmonary delivery via two different nebulizers and multivariate data analysis of aerosol mass distribution profiles. [2009]
Use of micafungin versus fluconazole for antifungal prophylaxis in neutropenic patients receiving hematopoietic stem cell transplantation. [2008.12]
Efficacy of single-dose liposomal amphotericin B or micafungin prophylaxis in a neutropenic murine model of invasive pulmonary aspergillosis. [2008.11]
In vivo pharmacodynamic target investigation for micafungin against Candida albicans and C. glabrata in a neutropenic murine candidiasis model. [2008.10]
Activity of amphotericin B, anidulafungin, caspofungin, micafungin, posaconazole, and voriconazole against Candida albicans with decreased susceptibility to fluconazole from APECED patients on long-term azole treatment of chronic mucocutaneous candidiasis. [2008.10]
Intravenous injection of micafungin counteracts Candida albicans-induced aggravation of duodenal ulcers caused by cysteamine in rats. [2008.09]
Micafungin Versus Liposomal Amphotericin B for Pediatric Patients With Invasive Candidiasis: Substudy of a Randomized Double-Blind Trial. [2008.08.01]
Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints. [2008.08]
Breakthrough cryptococcosis in a patient with systemic lupus erythematosus (SLE) receiving micafungin. [2008.08]
Clinical evaluation of the Sensititre YeastOne colorimetric antifungal panel for antifungal susceptibility testing of the echinocandins anidulafungin, caspofungin, and micafungin. [2008.07]
Economic analysis of micafungin versus liposomal amphotericin B for treatment of candidaemia and invasive candidiasis in Germany. [2008.06]
Ocular distribution of intravenously administered micafungin in rabbits. [2008.06]
Comparison of the dose-dependent activity and paradoxical effect of caspofungin and micafungin in a neutropenic murine model of invasive pulmonary aspergillosis. [2008.05]
|
